## FANCL Corporation

## Consolidated Financial Statements for the Third Quarter of the Fiscal Year Ending March 31, 2006

[^0]
## SUMMARY OF FINANCIAL STATEMENTS (consolidated)

Third quarter results for the Fiscal Year Ending March 31, 2006

## FANCL CORPORATION

January 31, 2006
Stock exchange listings: Tokyo $1^{\text {st }}$ section, code number 4921
Contact: Shoji Shiba
Executive Officer/General Manager of
www.fancl.co.jp Representative: Administrative Headquarters
Telephone: +81-45-226-1200
Kenji Fujiwara, President and Representative Director

1) Notes to preparation of these financial statements
(1) Use of simplified accounting methods: Yes

Details
Method of depreciation of fixed assets:

1. Tangible fixed assets
Nine-month portion of estimated amount for the year
2. Intangible fixed assets Nine-month portion of estimated amount for the year

Standard for stating income taxes: Calculated using the estimated annual tax rate based on the effective statutory tax rate Simplified procedures are used for amounts with an immaterial effect
(1) Changes from accounting methods used in most recent consolidated fiscal year: None
(2) Changes in scope of consolidation and application of equity method None
2) Consolidated results for the third quarter of Fiscal 2006 (April 1, 2005 to December 31, 2005)

| (1) Sales and Income | Millions of yen, rounded down |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Nine months ended December 31, 2005 |  | Nine months ended December 31, 2004 |  | Year ended March 31, 2005 |
|  |  | Change \% |  | nge \% |  |
| Net sales | 72,050 | 8.8 | 66,251 | 3.3 | 87,937 |
| Operating income. | 7,580 | 100.4 | 3,783 | (53.5) | 5,428 |
| Ordinary income | 8,015 | 101.4 | 3,979 | (52.6) | 5,490 |
| Net income ...... | 4,507 | 214.2 | 1,434 | (64.6) | 1,709 |
| Earnings per share ( $¥$ ) . | ¥211.30 |  | $¥ 67.40$ |  | ¥80.29 |
| Earnings per share (diluted) ( $¥$ )....................... | ¥209.29 |  | -- |  | $¥ 80.23$ |

Note: Year-on-year change for net sales, operating income, ordinary income and net income reflects a comparison with the same period in the previous fiscal year.

| (2) Consolidated Financial Position | Millions of yen, rounded down |  |  |
| :---: | :---: | :---: | :---: |
|  | As of December 31, 2005 | As of December 31, 2004 | As of March 31, 2005 |
| Total assets. | 83,611 | 78,245 | 79,416 |
| Shareholders' equity. | 70,375 | 65,931 | 66,203 |
| Shareholders' equity/total assets (\%) | 84.2\% | 84.3\% | 83.4\% |
| Shareholders' equity per share ( $¥$ ) . | $¥ 3,281.58$ | $¥ 3,098.15$ | $¥ 3,111.15$ |
|  | Millions of yen, rounded down |  |  |
| (3) Cash Flows | Nine months ended December 31, 2005 | Nine months ended December 31, 2004 | Year ended March 31, 2005 |
| Net cash provided by (used in) operating activities | 5,318 | 1,198 | 4,637 |
| Net cash used in investing activities. | $(3,723)$ | $(1,617)$ | $(4,807)$ |
| Net cash used in financing activities.. | (305) | $(1,027)$ | $(1,090)$ |
| Cash and cash equivalents at end of period | 23,596 | 22,120 | 22,307 |

3) Consolidated forecasts for the fiscal year ending March 31, 2006 (April 1, 2005 to March 31, 2006)

|  | Millions of yen |  |
| :---: | :---: | :---: |
|  | FY ending March 31, 2006 |  |
| Net sales .......................................................................... | 95,000 |  |
| Ordinary income ................................................................. | 9,000 |  |
| Net income ......................................................................... | 4,700 |  |

Note: Consolidated net income per share forecast for the fiscal year ending March 31, 2006: $¥ 220.04$

This forecast contains forward-looking statements that are based on management's estimates, assumptions and projections at the time of publication. A number of factors could cause actual results to differ materially from expectations.

Qualitative information regarding this results forecast
Performance in largely in line with expectations and there are no changes to the forecast made in the interim report dated November 1, 2005.

## Consolidated operating results ${ }^{1}$

The domestic economy in the period under review has been gradually recovering due to such factors as improved corporate earnings and an increase in corporate expenditure, however a full-fledged recovery in consumer spending has yet to occur.

In the cosmetics industry there was continued strength, with sales of skincare products performing well.
In the nutritional supplements industry, a boom in products such as Co-enzyme $Q_{10}$ and Alpha Lipoic Acid resulted in both market expansion and a sharp increase in competition.

## Net Sales

Consolidated net sales increased $8.8 \%$ to $¥ 72,050$ million. This was largely the result of strong sales in our core businesses of cosmetics and nutritional supplements primarily through our retail sales channel.

## Ordinary Income

Consolidated ordinary income increased $101.4 \%$ to $¥ 8,015$ million, and the ordinary income margin increased 5.1 percentage points to $11.1 \%$.

## Net Income

Consolidated net income for the period under review increased $214.2 \%$ to $¥ 4,507$ million, and net income margin increased 4.2 percentage points to $6.3 \%$.

## Consolidated financial position

Cash and cash equivalents as of December 31, 2005 were $¥ 23,596$ million, an increase of $¥ 1,289$ million over the end of the previous fiscal year. The main contributing factors are detailed below.

## Cash flow from operating activities

Cash flow from operating activities during the nine-month period under review was $¥ 5,318$ million. Main contributing factors included income before income taxes of $¥ 7,565$ million and an increase of $¥ 1,851$ million in depreciation and amortization, while factors reducing operating cash flow included a $¥ 2,020$ million increase in accounts receivable and corporate tax payments of $¥ 2,840$ million.

## Cash flow from investing activities

Cash flow used in investing activities during the period under review was $¥ 3,723$ million. This was largely the result of $¥ 1,755$ million used to open and renovate retail stores.

## Cash flow from financing activities

Cash flow from financing activities during the period under review was $¥ 305$ million. This was largely due to an outflow of $¥ 1,018$ million for the distribution of dividends and an inflow of $¥ 676$ million from the sale of treasury stock.

[^1]1. Consolidated Third Quarter Financial Statements

| Consolidated Third Quarter Balance Sheets |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen, rounded down |  |  |  |  |  |
|  | As of December 31, 2005 |  | As of December 31, 2004 |  | As ofMarch 31, 2005 |  |
| ASSETS |  | \% |  | \% |  | \% |
| I. Current assets: |  |  |  |  |  |  |
| Cash and cash equivalents. | 19,169 |  | 14,386 |  | 17,380 |  |
| Notes and accounts receivable | 10,734 |  | 9,524 |  | 8,713 |  |
| Marketable securities | 6,129 |  | 7,733 |  | 4,926 |  |
| Inventories | 7,169 |  | 6,180 |  | 5,663 |  |
| Others .................................................... | 1,502 |  | 2,409 |  | 2,395 |  |
| Total current assets................................ | 44,705 | 53.5 | 40,234 | 51.4 | 39,079 | 49.2 |
| II. Fixed assets: |  |  |  |  |  |  |
| Tangible fixed assets |  |  |  |  |  |  |
| Buildings and structures.. | 12,477 |  | 12,403 |  | 12,781 |  |
| Land. | 10,720 |  | 10,847 |  | 10,916 |  |
| Others | 2,654 |  | 2,947 |  | 2,835 |  |
| Total tangible fixed assets....................... | 25,852 | 30.9 | 26,198 | 33.5 | 26,533 | 33.4 |
| Intangible fixed assets | 1,299 | 1.6 | 1,280 | 1.6 | 1,222 | 1.5 |
| Investments and other assets |  |  |  |  |  |  |
| Investments securities | 1,977 |  | 1,107 |  | 1,954 |  |
| Long-term loans receivable. | 683 |  | 985 |  | 659 |  |
| Guarantee money .. | 2,673 |  | 2,475 |  | 2,526 |  |
| Others .................................................... | 6,419 |  | 5,963 |  | 7,439 |  |
| Total investments and other assets ........... | 11,754 | 14.0 | 10,531 | 13.5 | 12,579 | 15.9 |
| Total fixed assets ................................. | 38,906 | 46.5 | 38,010 | 48.6 | 40,336 | 50.8 |
| Total Assets............................................. | 83,611 | 100.0 | 78,245 | 100.0 | 79,416 | 100.0 |
| LIABILITIES |  |  |  |  |  |  |
| I. Current liabilities: |  |  |  |  |  |  |
| Notes and accounts payable.. | 4,171 |  | 3,725 |  | 3,049 |  |
| Accrued liabilities.. | 3,679 |  | 3,080 |  | 3,985 |  |
| Accrued income taxes. | 1,839 |  | 1,278 |  | 1,914 |  |
| Others ..................................................... | 1,706 |  | 1,513 |  | 1,509 |  |
| Total current liabilities .............................. | 11,397 | 13.6 | 9,598 | 12.2 | 10,457 | 13.2 |
| II. Long-term liabilities: |  |  |  |  |  |  |
| Allowance for retirement bonuses... | 1,264 |  | 1,120 |  | 1,194 |  |
| Allowance for directors' retirement bonuses . | 177 |  | 1,108 |  | 1,117 |  |
| Others .................................................... | 397 |  | 485 |  | 442 |  |
| Total long-term liabilities ........................... | 1,838 | 2.2 | 2,714 | 3.5 | 2,754 | 3.4 |
| Total liabilities. | 13,236 | 15.8 | 12,313 | 15.7 | 13,212 | 16.6 |
| SHAREHOLDERS' EQUITY |  |  |  |  |  |  |
| I. Common stock | 10,795 | 12.9 | 10,795 | 13.8 | 10,795 | 13.6 |
| II. Capital reserve ..................................... | 11,806 | 14.1 | 11,706 | 15.0 | 11,706 | 14.8 |
| III. Retained earnings .... | 54,650 | 65.4 | 50,897 | 65.1 | 51,172 | 64.4 |
| IV. Net Unrealized holding gain on other securities | 43 | 0.1 | 22 | 0.0 | 26 | 0.0 |
| V. Foreign currency translation adjustment..... | (4) | (0.0) | (4) | (0.0) | (4) | (0.0) |
| VI. Treasury stock ...................................... | $(6,915)$ | (8.3) | $(7,484)$ | (9.6) | $(7,492)$ | (9.4) |
| Total shareholders' equity ...................... | 70,375 | 84.2 | 65,931 | 84.3 | 66,203 | 83.4 |
| Total Liabilities and Shareholders' Equity.. | 83,611 | 100.0 | 78,245 | 100.0 | 79,416 | 100.0 |


| Consolidated Third Quarter Statements of Income |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen, rounded down |  |  |  |  |  |
|  | April 1 to December 31, 2005 |  | April 1 to December 31, 2004 |  | FY ended March 31, |  |
| Net sales................. | 72,050 | 100.0 | 66,251 | 100.0 | 87,937 | 100.0 |
| Cost of sales.. | 24,811 | 34.4 | 22,643 | 34.2 | 30,031 | 34.2 |
| Gross profit ... | 47,238 | 65.6 | 43,607 | 65.8 | 57,905 | 65.8 |
| Selling, general and administrative expenses | 39,658 | 55.1 | 39,824 | 60.1 | 52,476 | 59.7 |
| Operating income........................ | 7,580 | 10.5 | 3,783 | 5.7 | 5,428 | 6.2 |
| Net operating income .................... | 652 | 0.9 | 546 | 0.8 | 770 | 0.9 |
| Interest and dividend income. | 43 |  | 34 |  | 56 |  |
| Other non-operating income. | 609 |  | 512 |  | 713 |  |
| Net operating expenses ....... | 217 | 0.3 | 350 | 0.5 | 709 | 0.8 |
| Loss on disposal of obsolete inventories $\qquad$ | 161 |  | 328 |  | 681 |  |
| Other non-operating expenses | 55 |  | 21 |  | 27 |  |
| Ordinary income........................... | 8,015 | 11.1 | 3,979 | 6.0 | 5,490 | 6.2 |
| Extraordinary income....................... | 3 | 0.0 | 57 | 0.1 | 57 | 0.1 |
| Extraordinary expenses ................... | 453 | 0.6 | 505 | 0.8 | 1,181 | 1.3 |
| Impairment loss .................. | 237 |  | -- |  | -- |  |
| Loss on disposal of fixed assets | 83 |  | 204 |  | 335 |  |
| Directors' retirement benefit expenses | 71 |  | 18 |  | 39 |  |
| Other extraordinary expenses ........... | 61 |  | 282 |  | 806 |  |
| Income before income taxes............. | 7,565 | 10.5 | 3,531 | 5.3 | 4,366 | 5.0 |
| Income taxes ................................... | 3,058 | 4.2 | 2,096 | 3.2 | 2,657 | 3.1 |
| Net income ..................................... | 4,507 | 6.3 | 1,434 | 2.1 | 1,709 | 1.9 |


4. Segment Information

Business Segments
April 1 to December 31, 2005

|  | Cosmetics <br> Business | Nutritional <br> Supplements <br> Business | Other <br> Businesses | Total | Eliminations <br> or Corporate | Consolidated |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales: <br> (1) Sales to external <br> customers | 31,029 | 25,478 | 15,541 | 72,050 | -- | 72,050 |
| (2) Inter-segment <br> sales or transfers | -- | -- | -- | -- | -- | -- |
| Total sales | 31,029 | 25,478 | 15,541 | 72,050 | --205 | 72,050 |
| Operating expenses | 26,438 | 21,148 | 15,618 | 63,205 | 1,264 | 64,469 |
| Operating income <br> (loss) | 4,590 | 4,330 | $\triangle 76$ | 8,845 | $(1,264)$ | 7,580 |

April 1 to December 31, 2004

|  | Cosmetics <br> Business | Nutritional <br> Supplements <br> Business | Other <br> Businesses | Total | Eliminations <br> or Corporate | Consolidated |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales: <br> (1) Sales to external <br> customers | 28,028 | 23,157 | 15,064 | 66,251 | -- | 66,251 |
| (2) Inter-segment <br> sales or transfers | -- | -- | -- | -- | -- | -- |
| Total sales | 28,028 | 23,157 | 15,064 | 66,251 | -- | 66,251 |
| Operating expenses | 24,403 | 19,887 | 16,608 | 60,899 | 1,567 | 62,467 |
| Operating income <br> (loss) | 3,625 | 3,269 | $(1,544)$ | 5,351 | $(1,567)$ | 3,783 |

## Operating Results by Segment ${ }^{2}$

## 1) Cosmetics Business

Product development of FANCL cosmetics has been centered on ingredient functionality in an effort to revitalize core products. Meanwhile, Facial Washing Powder was renewed in August and Anti-aging Essence -Beauty Concentrate was launched in December. For ATTENIR cosmetics, Micro Collagen-based essence Lift Wrinkle Serum was launched in October.

## SALES

Sales in the cosmetics business increased $10.7 \%$ over the same period last year, to $¥ 31,029$ million.
(Millions of yen)

|  | April 1 to |  | April 1 to |  | $\%$ |
| :--- | ---: | ---: | ---: | ---: | ---: |
|  | December 31, 2005 |  | December 31, 2004 |  |  |
|  | Amount | $\%$ of total | Amount | $\%$ of total |  |
| FANCL Cosmetics | 23,482 | 75.7 | 20,946 | 74.7 | 12.1 |
| ATTENIR Cosmetics | 7,279 | 23.4 | 6,901 | 24.6 | 5.5 |
| Other | 267 | 0.9 | 180 | 0.7 | 48.9 |
| Total | 31,029 | 100.0 | 28,028 | 100.0 | 10.7 |


|  | April 1 toDecember 31, 2005 |  | $\begin{gathered} \text { April } 1 \text { to } \\ \text { December 31, } 2004 \\ \hline \end{gathered}$ |  | \% change |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total |  |
| Mail-order sales | 18,292 | 58.9 | 17,417 | 62.1 | 5.0 |
| Retail store sales | 10,142 | 32.7 | 8,565 | 30.6 | 18.4 |
| Other | 2,594 | 8.4 | 2,045 | 7.3 | 26.9 |
| Total | 31,029 | 100.0 | 28,028 | 100.0 | 10.7 |

## Mail-order sales

Mail-order sales increased $5.0 \%$ to $¥ 18,292$ million. Sales of FANCL Cosmetics increased $5.4 \%$ to $¥ 11,602$ million, primarily due to a boom in sales of FENATTY, Mild Cleansing Oil, and Facial Washing Powder as a result of renewals made over the previous and current reporting period. Customer numbers have also been trending upwards and as of December 31, 2005 had recovered to the record levels of FANCL cosmetic sales achieved in fiscal year ending March 2000.

Sales of ATTENIR Cosmetics increased $4.3 \%$ to $¥ 6,685$ million due to the effects of new products and effective sales promotion activities.

## Retail store sales

Retail store sales grew $18.4 \%$ to $¥ 10,142$ million, with continued strong sales at existing stores along with a contribution from new store openings.

## Other sales channels

Sales in other channels increased $26.9 \%$ to $¥ 2,594$ million. This was the result of strong performance from overseas and convenience store sales.

## OPERATING INCOME

Operating income in this segment increased $26.6 \%$ to $¥ 4,590$ million due to a large increase in revenues, despite an increase in expenditure on sales and advertising. The operating income margin increased 1.9 percentage points to $14.8 \%$.

[^2]
## 2) Nutritional Supplements Business

In the Nutritional Supplements Business, new products such as HTC Collagen with its unique ingredients and Bright-age Ex with its anti-aging ingredient were launched in April and December respectively, and efforts to enhance beauty supplement foods were also undertaken. Additionally, in June the highly anticipated Alpha Lipoic Acid product was launched.

## SALES

Sales in the nutritional supplements business increased $10.0 \%$ to $¥ 25,478$ million.

|  | April 1 toDecember 31, 2005 |  | April 1 toDecember 31, 2004 |  | \% change |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total |  |
| Mail-order sales | 13,015 | 51.1 | 12,364 | 53.4 | 5.3 |
| Retail store sales | 6,328 | 24.8 | 5,309 | 22.9 | 19.2 |
| Other | 6,134 | 24.1 | 5,483 | 23.7 | 11.9 |
| Total | 25,478 | 100.0 | 23,157 | 100.0 | 10.0 |

## Mail-order sales

Mail-order sales grew $5.3 \%$ to $¥ 13,015$ million, due to strong sales of Co-enzyme $Q_{10}$ and new products such as Alpha Lipoic Acid and HTC Collagen.

## Retail store sales

Retail store sales grew $19.2 \%$ to $¥ 6,328$ million, supported by an increase in the number of new and converted FANCL House J stores (which generate a high proportion of their sales from nutritional supplements), and strong sales at existing stores.

## Other sales channels

Sales in other channels increased $11.9 \%$ to $¥ 6,134$ million due to an expansion of the customer base.

## OPERATING INCOME

Operating income in this segment increased $32.4 \%$ to $¥ 4,330$ million, with a decrease in gross margin from an increase in the price of materials more than offset by efficiencies achieved in areas such as sales and advertising expenses. The operating income margin increased 2.9 percentage points to $17.0 \%$.

## 3) Other businesses

## SALES

Sales in Other business increased $3.2 \%$ to $¥ 15,541$ million.

|  | April 1 to <br> December 31, 2005 |  | April 1 to <br> December 31, 2004 |
| :--- | ---: | ---: | ---: |
| Hatsuga Genmai business | 3,388 | 3,945 | $(14.1)$ |
| Kale juice business | 2,996 | 2,613 | 14.7 |
| IIMONO OHKOKU <br> mail-order business | 6,280 | 5,447 | 15.3 |
| Other related businesses | 2,875 | 3,057 | $(5.9)$ |
| Total | 15,541 | 15,064 | 3.2 |

## Hatsuga Genmai business

Mail order and wholesale sales were lower despite the launch of Newly Germinated Rice, which is a product produced by removing half of the husk to create a similar item to white rice.

## Kale juice business

Sales of Super Kale Juice Twintose Formula, a high value-added frozen product, began in July. Sales increased due to strong sales of powder-type kale juice with Twintose.

## IIMONO OHKOKU Co., Ltd. mail-order business

Sales increased supported by strong sales in seasonal products and sales of Walking Shoes.

## Other related businesses

Sales declined, due to poor sales of household sundries.

## OPERATING INCOME

Operating income in this segment was $¥ 76$ million with a $¥ 1,467$ million reduction in operating losses due to the return to profitability of the Kale juice and the IIMONO OHKOKU mail order business.

Number of stores by business type

|  | As of December $31,2005$ | Compared with March 31, 2005 |
| :---: | :---: | :---: |
| FANCL House | 109 | -1 |
| FANCL House J | 60 | +23 |
| Genki Station | 9 | - |
| ATTENIR Shop | 10 | + 1 |
| Other | 3 | - |
| Total | 191 | +23 |

Reference:

| Non-consolidated Third Quarter Balance Sheets |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen, rounded down |  |  |  |  |  |
|  | As ofDecember 31, 2005 |  | As ofDecember 31, 2004 |  | As ofMarch 31, 2005 |  |
| ASSETS |  | \% |  | \% |  | \% |
| I. Current assets: |  |  |  |  |  |  |
| Cash and cash equivalents. | 9,480 |  | 6,041 |  | 8,250 |  |
| Notes and accounts receivable | 8,829 |  | 7,884 |  | 7,107 |  |
| Marketable securities . | 6,129 |  | 7,733 |  | 4,926 |  |
| Inventories | 2,925 |  | 3,585 |  | 3,047 |  |
| Others ................................................... | 1,904 |  | 2,878 |  | 2,928 |  |
| Total current assets................................ | 29,269 | 42.6 | 28,124 | 43.1 | 26,260 | 39.9 |
| II. Fixed assets: |  |  |  |  |  |  |
| Tangible fixed assets |  |  |  |  |  |  |
| Buildings and structures. | 6,381 |  | 9,143 |  | 8,847 |  |
| Land. | 7,260 |  | 8,048 |  | 8,048 |  |
| Others. | 951 |  | 1,939 |  | 2,090 |  |
| Total tangible fixed assets........................ | 14,592 | 21.2 | 19,131 | 29.3 | 18,986 | 28.8 |
| Intangible fixed assets | 1,016 | 1.5 | 686 | 1.1 | 708 | 1.1 |
| Investments and other assets |  |  |  |  |  |  |
| Investments securities | 1,078 |  | 208 |  | 1,041 |  |
| Long-term loans receivable. | 6,876 |  | 6,831 |  | 6,858 |  |
| Guarantee money . | 2,393 |  | 2,188 |  | 2,242 |  |
| Others .................................................... | 13,462 |  | 8,042 |  | 9,749 |  |
| Total investments and other assets ........... | 23,811 | 34.7 | 17,271 | 26.5 | 19,891 | 30.2 |
| Total fixed assets . | 39,420 | 57.4 | 37,089 | 56.9 | 39,586 | 60.1 |
| Total Assets.............................................. | 68,690 | 100.0 | 65,213 | 100.0 | 65,847 | 100.0 |
| LIABILITIES |  | \% |  | \% |  | \% |
| I. Current liabilities: |  |  |  |  |  |  |
| Notes and accounts payable. | 3,305 |  | 2,483 |  | 2,010 |  |
| Accrued liabilities | 2,678 |  | 2,734 |  | 2,895 |  |
| Accrued income taxes. | 1,100 |  | 712 |  | 1,217 |  |
| Others ..................................................... | 1,400 |  | 1,146 |  | 1,012 |  |
| Total current liabilities .............................. | 8,485 | 12.4 | 7,076 | 10.9 | 7,136 | 10.8 |
| II. Long-term liabilities: |  |  |  |  |  |  |
| Allowance for retirement bonuses........ | 805 |  | 875 |  | 899 |  |
| Allowance for directors' retirement bonuses . | 177 |  | 1,108 |  | 1,117 |  |
| Others ..................................................... | 90 |  | 79 |  | 60 |  |
| Total long-term liabilities .......................... | 1,073 | 1.5 | 2,063 | 3.2 | 2,078 | 3.2 |
| Total liabilities ...................................... | 9,558 | 13.9 | 9,139 | 14.0 | 9,214 | 14.0 |
| SHAREHOLDERS' EQUITY |  |  |  |  |  |  |
| I. Common stock ................................. | 10,795 | 15.7 | 10,795 | 16.6 | 10,795 | 16.4 |
| II. Capital reserve ................................... | 11,806 | 17.2 | 11,706 | 18.0 | 11,706 | 17.8 |
| III. Retained earnings ................................ | 43,401 | 63.2 | 41,035 | 62.9 | 41,597 | 63.2 |
| IV. Net Unrealized holding gain on other securities. $\qquad$ | 43 | 0.1 | 21 | 0.0 | 26 | 0.0 |
| V. Treasury stock ...................................... | $(6,915)$ | (10.1) | $(7,484)$ | (11.5) | $(7,492)$ | (11.4) |
| Total shareholders' equity................... | 59,131 | 86.1 | 56,073 | 86.0 | 56,633 | 86.0 |
| Total Liabilities and Shareholders' Equity.. | 68,690 | 100.0 | 65,213 | 100.0 | 65,847 | 100.0 |


| Non-consolidated Third Quarter Statements of Income |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen, rounded down |  |  |  |  |  |
|  | April 1 to December 31, 2005 |  | April 1 to December 31, 2004 |  | FY ended March 31, 2005 |  |
| Net sales........................................ | 56,525 | 100.0 | 52,021 | 100.0 | 69,170 | 100.0 |
| Cost of sales. | 20,748 | 36.7 | 18,226 | 35.0 | 24,176 | 35.0 |
| Gross profit ... | 35,776 | 63.3 | 33,794 | 65.0 | 44,994 | 65.0 |
| Selling, general and administrative expenses | 31,393 | 55.5 | 31,824 | 61.2 | 41,856 | 60.5 |
| Operating income......................... | 4,383 | 7.8 | 1,970 | 3.8 | 3,138 | 4.5 |
| Net operating income ...................... | 1,061 | 1.9 | 1,000 | 1.9 | 1,394 | 2.0 |
| Interest and dividend income. | 144 |  | 200 |  | 236 |  |
| Other non-operating income.......... | 917 |  | 799 |  | 1,157 |  |
| Net operating expenses ....... | 187 | 0.3 | 320 | 0.6 | 625 | 0.9 |
| Loss on disposal of obsolete inventories $\qquad$ | 140 |  | 299 |  | 599 |  |
| Other non-operating expenses | 46 |  | 21 |  | 25 |  |
| Ordinary income............................ | 5,257 | 9.3 | 2,649 | 5.1 | 3,907 | 5.6 |
| Extraordinary income....................... | 2 | 0.0 | -- | -- | -- | -- |
| Extraordinary expenses ................... | 450 | 0.8 | 409 | 0.8 | 679 | 1.0 |
| Income before income taxes............. | 4,809 | 8.5 | 2,240 | 4.3 | 3,227 | 4.7 |
| Income taxes ........................................... | 1,939 | 3.4 | 942 | 1.8 | 1,367 | 1.9 |
| Net income ..................................... | 2,869 | 5.1 | 1,297 | 2.5 | 1,860 | 2.7 |


[^0]:    This document has been translated from the original Japanese as a guide for non-Japanese investors. It contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. Actual financial results may differ materially depending on a number of factors, including changing economic conditions, legislative and regulatory developments, delay in new product launches, and pricing and product initiatives of competitors.

[^1]:    ${ }^{1}$ Note: All comparisons are with the first nine months of the previous fiscal year, unless otherwise stated.

[^2]:    ${ }^{2}$ Note: All comparisons are with the first nine months of the previous fiscal year, unless stated otherwise.

